Loading...

Jubilant Life Sciences

BSE:530019
Snowflake Description

Undervalued with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
530019
BSE
₹73B
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Jubilant Life Sciences Limited manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals, and nutritional products. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Jubilant Life Sciences has significant price volatility in the past 3 months.
530019 Share Price and Events
7 Day Returns
-0.9%
BSE:530019
-0.2%
IN Pharmaceuticals
-0.8%
IN Market
1 Year Returns
-38.2%
BSE:530019
-14.5%
IN Pharmaceuticals
-0.9%
IN Market
530019 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Jubilant Life Sciences (530019) -0.9% -24.1% -46% -38.2% 34.1% 127.3%
IN Pharmaceuticals -0.2% -3.6% -10.7% -14.5% -16.7% 15.6%
IN Market -0.8% 6% 1.4% -0.9% 33.9% 42.9%
1 Year Return vs Industry and Market
  • 530019 underperformed the Pharmaceuticals industry which returned -14.5% over the past year.
  • 530019 underperformed the Market in India which returned -0.9% over the past year.
Price Volatility
530019
Industry
5yr Volatility vs Market

Value

 Is Jubilant Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Jubilant Life Sciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Jubilant Life Sciences.

BSE:530019 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 15.6%
Perpetual Growth Rate 10-Year IN Government Bond Rate 7.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BSE:530019
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year IN Govt Bond Rate 7.6%
Equity Risk Premium S&P Global 8.6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.64 (1 + (1- 35%) (64.57%))
0.938
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.938 * 8.6%)
15.62%

Discounted Cash Flow Calculation for BSE:530019 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Jubilant Life Sciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BSE:530019 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (INR, Millions) Source Present Value
Discounted (@ 15.62%)
2019 6,942.75 Analyst x4 6,004.78
2020 8,337.20 Analyst x5 6,236.65
2021 10,270.20 Analyst x5 6,644.71
2022 11,014.44 Est @ 7.25% 6,163.46
2023 11,822.64 Est @ 7.34% 5,721.93
2024 12,697.67 Est @ 7.4% 5,315.18
2025 13,643.13 Est @ 7.45% 4,939.39
2026 14,663.25 Est @ 7.48% 4,591.51
2027 15,762.84 Est @ 7.5% 4,268.99
2028 16,947.31 Est @ 7.51% 3,969.69
Present value of next 10 years cash flows ₹53,856.29
BSE:530019 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ₹16,947.31 × (1 + 7.55%) ÷ (15.62% – 7.55%)
₹225,848.69
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ₹225,848.69 ÷ (1 + 15.62%)10
₹52,902.22
BSE:530019 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ₹53,856.29 + ₹52,902.22
₹106,758.51
Equity Value per Share
(INR)
= Total value / Shares Outstanding
= ₹106,758.51 / 155.77
₹685.34
BSE:530019 Discount to Share Price
Calculation Result
Value per share (INR) From above. ₹685.34
Current discount Discount to share price of ₹471.50
= -1 x (₹471.50 - ₹685.34) / ₹685.34
31.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Jubilant Life Sciences is available for.
Intrinsic value
31%
Share price is ₹471.5 vs Future cash flow value of ₹685.34
Current Discount Checks
For Jubilant Life Sciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Jubilant Life Sciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Jubilant Life Sciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Jubilant Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Jubilant Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BSE:530019 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹36.86
BSE:530019 Share Price ** BSE (2019-06-14) in INR ₹471.5
India Pharmaceuticals Industry PE Ratio Median Figure of 115 Publicly-Listed Pharmaceuticals Companies 18.47x
India Market PE Ratio Median Figure of 2,824 Publicly-Listed Companies 15.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Jubilant Life Sciences.

BSE:530019 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BSE:530019 Share Price ÷ EPS (both in INR)

= 471.5 ÷ 36.86

12.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jubilant Life Sciences is good value based on earnings compared to the IN Pharmaceuticals industry average.
  • Jubilant Life Sciences is good value based on earnings compared to the India market.
Price based on expected Growth
Does Jubilant Life Sciences's expected growth come at a high price?
Raw Data
BSE:530019 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 12.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
29.6%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 31 Publicly-Listed Pharmaceuticals Companies 1.36x
India Market PEG Ratio Median Figure of 521 Publicly-Listed Companies 1.34x

*Line of best fit is calculated by linear regression .

BSE:530019 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 12.79x ÷ 29.6%

0.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jubilant Life Sciences is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Jubilant Life Sciences's assets?
Raw Data
BSE:530019 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹309.00
BSE:530019 Share Price * BSE (2019-06-14) in INR ₹471.5
India Pharmaceuticals Industry PB Ratio Median Figure of 134 Publicly-Listed Pharmaceuticals Companies 1.67x
India Market PB Ratio Median Figure of 3,654 Publicly-Listed Companies 1.01x
BSE:530019 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BSE:530019 Share Price ÷ Book Value per Share (both in INR)

= 471.5 ÷ 309.00

1.53x

* Primary Listing of Jubilant Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jubilant Life Sciences is good value based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Jubilant Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Jubilant Life Sciences has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Jubilant Life Sciences expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Jubilant Life Sciences expected to grow at an attractive rate?
  • Jubilant Life Sciences's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Jubilant Life Sciences's earnings growth is expected to exceed the India market average.
  • Jubilant Life Sciences's revenue growth is positive but not above the India market average.
Annual Growth Rates Comparison
Raw Data
BSE:530019 Future Growth Rates Data Sources
Data Point Source Value (per year)
BSE:530019 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 29.6%
BSE:530019 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 7.5%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.3%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 11.6%
India Market Earnings Growth Rate Market Cap Weighted Average 16.6%
India Market Revenue Growth Rate Market Cap Weighted Average 9.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BSE:530019 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BSE:530019 Future Estimates Data
Date (Data in INR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 105,949 15,307 10,913 7
2020-03-31 97,608 13,836 9,498 7
BSE:530019 Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 91,108 5,745
2018-12-31 89,772 8,286
2018-09-30 86,679 7,803
2018-06-30 80,402 6,982
2018-03-31 75,178 13,032 6,428
2017-12-31 68,641 6,381
2017-09-30 62,545 5,449
2017-06-30 59,982 5,613
2017-03-31 58,614 12,685 5,757
2016-12-31 58,013 4,763
2016-09-30 57,097 4,795
2016-06-30 57,762 4,612

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Jubilant Life Sciences's earnings are expected to grow significantly at over 20% yearly.
  • Jubilant Life Sciences's revenue is expected to grow by 7.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BSE:530019 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Jubilant Life Sciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:530019 Future Estimates Data
Date (Data in INR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 68.94 74.90 62.87 7.00
2020-03-31 60.01 66.10 54.99 7.00
BSE:530019 Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 36.86
2018-12-31 53.18
2018-09-30 50.08
2018-06-30 44.81
2018-03-31 41.25
2017-12-31 40.94
2017-09-30 34.93
2017-06-30 35.98
2017-03-31 36.93
2016-12-31 29.88
2016-09-30 30.13
2016-06-30 28.96

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Jubilant Life Sciences is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Jubilant Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Jubilant Life Sciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Jubilant Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Jubilant Life Sciences's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Jubilant Life Sciences has delivered over 20% year on year earnings growth in the past 5 years.
  • Jubilant Life Sciences's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Jubilant Life Sciences's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
Earnings and Revenue History
Jubilant Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Jubilant Life Sciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BSE:530019 Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 91,108.20 5,744.60 19,259.60
2018-12-31 89,771.95 8,286.16 19,458.33
2018-09-30 86,678.55 7,803.16 18,691.03
2018-06-30 80,401.90 6,981.70 16,971.40
2018-03-31 75,178.35 6,428.06 16,186.83
2017-12-31 68,640.63 6,380.73 14,747.68
2017-09-30 62,545.23 5,449.33 13,609.98
2017-06-30 59,982.00 5,612.90 12,453.50
2017-03-31 58,614.33 5,756.53 12,791.88
2016-12-31 58,012.50 4,762.75 12,381.56
2016-09-30 57,097.00 4,795.05 12,107.16
2016-06-30 57,761.50 4,611.55 11,929.26
2016-03-31 57,491.33 3,918.31 11,673.57
2015-12-31 58,375.87 4,035.36 16,032.88
2015-09-30 59,036.17 2,754.46 15,917.88
2015-06-30 58,116.67 655.16 15,778.68
2015-03-31 58,262.47 -577.64 11,284.12
2014-12-31 58,862.63 -16.80 14,542.67
2014-09-30 58,836.63 1,529.10 14,636.07
2014-06-30 58,641.00 1,664.40 11,213.10
2014-03-31 58,033.63 1,090.40 14,956.81
2013-12-31 55,983.02 -207.43 13,800.41
2013-09-30 54,658.32 -1,374.83 13,373.11
2013-06-30 52,497.42 950.97 12,970.01
2013-03-31 51,659.50 1,527.27 12,719.46
2012-12-31 49,749.76 1,201.71 12,015.94
2012-09-30 47,664.06 150.91 11,914.24
2012-06-30 45,479.70 -575.50 8,780.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Jubilant Life Sciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Jubilant Life Sciences used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • Jubilant Life Sciences's use of capital has not improved over the past 3 years (Return on Capital Employed).
X
Past performance checks
We assess Jubilant Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Jubilant Life Sciences has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Jubilant Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Jubilant Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Jubilant Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jubilant Life Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Jubilant Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Jubilant Life Sciences Company Filings, last reported 2 months ago.

BSE:530019 Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 48,090.20 47,426.00 14,773.20
2018-12-31 45,447.70 38,493.70 6,232.90
2018-09-30 45,447.70 38,493.70 6,232.90
2018-06-30 40,350.10 32,926.60 3,370.70
2018-03-31 40,350.08 34,688.89 2,703.96
2017-12-31 37,309.10 35,945.70 4,119.70
2017-09-30 37,309.10 35,945.70 4,119.70
2017-06-30 33,967.50 38,489.80 4,904.40
2017-03-31 33,886.55 40,452.85 4,677.55
2016-12-31 33,631.30 37,783.40 3,479.50
2016-09-30 33,631.30 37,783.40 3,479.50
2016-06-30 29,095.69 45,167.20 3,487.43
2016-03-31 29,281.23 44,932.55 3,468.84
2015-12-31 27,091.40 35,658.20 3,735.40
2015-09-30 27,091.40 35,658.20 3,735.40
2015-06-30 24,535.16 47,931.18 4,009.92
2015-03-31 24,535.16 47,931.18 4,009.92
2014-12-31 27,401.20 47,479.40 4,117.70
2014-09-30 27,401.20 47,479.40 4,117.70
2014-06-30 27,844.50 29,047.10 4,795.30
2014-03-31 27,844.49 43,952.82 4,852.95
2013-12-31 26,321.20 28,270.90 1,393.20
2013-09-30 26,321.20 28,270.90 1,393.20
2013-06-30 26,058.92 37,921.91 3,601.01
2013-03-31 25,876.62 42,451.97 3,601.01
2012-12-31 27,099.50 36,932.70 3,111.50
2012-09-30 27,099.50 36,932.70 3,111.50
2012-06-30 23,987.20 36,069.90 2,671.90
  • Jubilant Life Sciences's level of debt (98.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (157.3% vs 98.6% today).
  • Debt is well covered by operating cash flow (27.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6.3x coverage).
X
Financial health checks
We assess Jubilant Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Jubilant Life Sciences has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Jubilant Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.95%
Current annual income from Jubilant Life Sciences dividends. Estimated to be 0.9% next year.
If you bought ₹2,000 of Jubilant Life Sciences shares you are expected to receive ₹19 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Jubilant Life Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.52%).
  • Jubilant Life Sciences's dividend is below the markets top 25% of dividend payers in India (2.04%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BSE:530019 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 74 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1450 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.5%
India Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BSE:530019 Future Dividends Estimate Data
Date (Data in ₹) Dividend per Share (annual) Avg. No. Analysts
2021-03-31 4.49 5.00
2020-03-31 4.01 6.00
BSE:530019 Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-05-17 4.500 0.897
2018-05-09 3.000 0.413
2017-05-23 3.000 0.407
2016-05-24 3.000 0.554
2015-08-07 3.000 0.808
2014-08-08 3.000 1.869
2014-05-26 3.000 1.535
2013-05-07 3.000 2.567
2012-08-01 3.000 1.522
2011-08-24 2.000 1.090
2010-05-10 2.000 0.837

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Jubilant Life Sciences has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Jubilant Life Sciences only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Jubilant Life Sciences's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (8.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be thoroughly covered by earnings (15.4x coverage).
X
Income/ dividend checks
We assess Jubilant Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Jubilant Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Jubilant Life Sciences has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Jubilant Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hari Bhartia
COMPENSATION ₹133,918,238
AGE 62
TENURE AS CEO 37.4 years
CEO Bio

Mr. Hari Shankar Bhartia, B.Tech serves as the Managing Director and Co-Chairman of Jubilant Biosys Limited and Jubilant Life Sciences Limited. Mr. Bhartia serves as a Managing Director of Jubilant Enpro, Ltd. He is the Founder of Jubilant Bhartia Group and serves as its Co-Chairman. He is a Co-Chairman of Jubilant Pharma Limited since January 15, 2018. He is Founder of Jubilant Foodworks Limited. He served as the President of Confederation of Indian Industry from 2010 to 2011. He joined Jubilant Life Sciences Limited on January 1, 1982. He has 36 years of experience in Pharmaceuticals, specialty chemicals, Bio-technology, Food, Oil & Gas (Exploration and Production), Aerospace, Information technology and other sectors. As Master Franchisee, Mr. Bhartia established Domino’s Pizza India as the largest fast food chain in the country. He has also contributed actively through deep involvement and lead roles in the Young President Organisation Inc. (YPO). Mr. Bhartia' s role in institutional work includes his role in various capacities with Indian Institute of Technology (IIT), Delhi and IIT Kanpur. He serves as the Non-Executive Co-Chairman of Jubilant Energy NV and has been its Director since June 14, 2007. He serves as the Co-Chairman of Jubilant Energy Limited and Jubilant Foodworks Limited and has been its Founder and Non Executive Director since March 16, 1995. He served as the Chairman of Jubilant Industries Limited until July 19, 2017. He served as Chairman of Indian Institute of Technology, Kanpur and Confederation of Indian Industry, Northern Region from 1997 to 2003. He served as the Chairman of Expert Group to develop policy initiatives for Technician Education through the National Project Implementation Unit. He has been a Director of Jubilant Pharma Limited since March 23, 2014. He serves as a Director of Jubilant Life Sciences Limited, Jubilant Enpro Ltd., Geo-Enpro Petroleum Ltd., Dominos Pizza India Ltd., Enpro Secan India Ltd., Network Programs(I) Ltd. and Food Express Stores (I) Ltd. He serves as a Non-Executive Director of Shriram Pistons & Rings Limited. He served as Director of Vam Holdings Limited since March 6,2013. He serves as a Non-executive Independent Director of Television Eighteen India Ltd. He serves as a Member of Advisory Board of High Street Capital Private Limited. He has been a Director of Global Broadcast News Ltd. since September 7, 2007. He has been a Non-Executive Independent Director of Export Credit Guarantee Corporation of India Ltd., since December 20, 2010. He served as a Director of Jubilant Industries Limited from November 1, 2010 to July 19, 2017. He served as a Non-Executive Independent Director of TV18 Broadcast Limited from September 29, 2006 to June 30, 2015. He served as Director of ECGC Ltd. He served as a Non-Executive & Independent Director of Network18 Media & Investments Ltd. until July 7, 2014. He served as a Director of United States Educational Foundation in India (USEFI) and Indian Institute of Technology, Kanpur. He has been a Member in several educational and science and technology programmes of Government of India. He is a Member of Communication Working Group of Global Round Table on Climate Change, Columbia University, USA. He worked as Chairman of National Committee on Technical Education & Training of CII since 1998, Member or CII National Technology Council since 1998 and Chairman of National Committee on Chemicals and Petrochemicals from 1999 to 2000. He was Chairman of the Board of Governors of the Indian Institute of Management (IIM), Raipur & Indian Institute of Technology (IIT), Kanpur. He chairs the Board of Governors, Indian Institute of Management, Visakhapatnam. He is a member of several CEO's Forums and prominent being the India-USA CEO Forum and India-France CEO Forum. He is a regular participant at the World Economic Forum Annual Meeting in Davos and was Co-Chair of the Davos Annual Meeting of the World Economic Forum in 2015. His immense contributions have been recognized by various awards. He, along with his brother, was felicitated with the Entrepreneur of the Year Award at the prestigious AIMA Managing India Awards 2013, presented by the President of India. In 2010, the duo also shared the much-coveted Ernst & Young Entrepreneur of the Year Award for Life Sciences & Consumer Products category. Mr. Bhartia has been conferred Distinguished Alumni award by Indian Institute of Technology, Delhi in the year 2000. Mr. Bhartia received a B.Tech in Chemical Engineering from the Indian Institute of Technology, Delhi.

CEO Compensation
  • Hari's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
  • Hari's remuneration is higher than average for companies of similar size in India.
Management Team Tenure

Average tenure and age of the Jubilant Life Sciences management team in years:

12.8
Average Tenure
54
Average Age
  • The average tenure for the Jubilant Life Sciences management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Hari Bhartia

TITLE
Co-Chairman & MD
COMPENSATION
₹134M
AGE
62
TENURE
37.4 yrs

Rajagopal Sankaraiah

TITLE
CFO & Executive Director of Finance
COMPENSATION
₹63M
AGE
59
TENURE
16.8 yrs

Prakash Bisht

TITLE
Executive VP of Group Accounts
AGE
54

Ashutosh Agarwal

TITLE
Chief Scientific Officer
AGE
60
TENURE
20.8 yrs

Umesh Mehta

TITLE
Chief Information Officer
AGE
52
TENURE
8.8 yrs

Rajiv Shah

TITLE
Compliance Officer & Company Secretary
COMPENSATION
₹8M
TENURE
4.3 yrs

Sanjay Gupta

TITLE
Senior VP & Head of Legal
AGE
52
TENURE
4.6 yrs

Chandan Sengar

TITLE
President of Life Science Chemicals
AGE
54

Vimal Kulshrestha

TITLE
Senior VP & Business Unit Head of Ethanol and Speciality Gases
AGE
53

Arun Sharma

TITLE
CFO (LSI) & Executive VP of Corporate Finance
AGE
52
Board of Directors Tenure

Average tenure and age of the Jubilant Life Sciences board of directors in years:

2.1
Average Tenure
64.5
Average Age
  • The average tenure for the Jubilant Life Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Shyam Bhartia

TITLE
Chairman
AGE
66

Hari Bhartia

TITLE
Co-Chairman & MD
COMPENSATION
₹134M
AGE
62
TENURE
37.4 yrs

Rajesh Srivastava

TITLE
Whole-Time Director & CEO of Life Science Ingredients
COMPENSATION
₹6M
AGE
53
TENURE
1.4 yrs

Anant Pande

TITLE
President of Manufacturing & Whole-time Director
COMPENSATION
₹13M
AGE
55
TENURE
0.7 yrs

S. Sridhar

TITLE
Independent Non Executive Director
COMPENSATION
₹2M
AGE
66
TENURE
4.8 yrs

Sudha Pillai

TITLE
Independent Non Executive Director
COMPENSATION
₹2M
AGE
67
TENURE
5.8 yrs

Ashok Misra

TITLE
Independent Non Executive Director
COMPENSATION
₹1M
AGE
71
TENURE
4.8 yrs

Vivek Mehra

TITLE
Independent Director
COMPENSATION
₹1M
AGE
63
TENURE
2.1 yrs

Sushil Roongta

TITLE
Independent Director
COMPENSATION
₹1M
AGE
68
TENURE
2.1 yrs

Priyavrat Bhartia

TITLE
Non Executive Non Independent Director
AGE
42
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
12. Jun 19 Buy Miller Holdings Pte. Ltd. Company 10. Jun 19 10. Jun 19 975,000 ₹475.55 ₹463,661,211
12. Jun 19 Sell Rance Investment Holdings Limited Company 10. Jun 19 10. Jun 19 -975,000 ₹475.55 ₹-463,661,211
31. May 19 Buy Miller Holdings Pte. Ltd. Company 30. May 19 30. May 19 650,000 ₹501.10 ₹325,714,968
31. May 19 Sell Cumin Investments Ltd. Company 30. May 19 30. May 19 -650,000 ₹501.10 ₹-325,714,968
22. May 19 Buy Miller Holdings Pte. Ltd. Company 21. May 19 21. May 19 770,445 ₹566.55 ₹436,495,575
25. Mar 19 Buy Miller Holdings Pte. Ltd. Company 22. Mar 19 22. Mar 19 450,000 ₹757.50 ₹340,874,979
25. Mar 19 Sell Rance Investment Holdings Limited Company 22. Mar 19 22. Mar 19 -450,000 ₹757.50 ₹-340,874,979
19. Mar 19 Sell Renu Khanna Individual 14. Mar 19 14. Mar 19 -6,020 ₹865.37 ₹-5,209,500
20. Mar 19 Buy Jubilant Corporation Company 19. Mar 19 19. Mar 19 2,831,000 ₹844.00 ₹2,389,364,035
20. Mar 19 Sell Jubilant Organosys Ltd., ESOP Company 20. Mar 19 20. Mar 19 -3,474,601 ₹784.17 ₹-2,724,694,916
19. Mar 19 Buy Miller Holdings Pte. Ltd. Company 15. Mar 19 15. Mar 19 450,000 ₹866.00 ₹389,699,980
19. Mar 19 Sell Cumin Investments Ltd. Company 15. Mar 19 15. Mar 19 -450,000 ₹866.00 ₹-389,699,980
13. Mar 19 Sell Rajesh Srivastava Individual 01. Mar 19 12. Mar 19 -5,018 ₹840.29 ₹-4,136,127
12. Mar 19 Sell Cumin Investments Ltd. Company 07. Mar 19 07. Mar 19 -650,000 ₹765.85 ₹-497,802,478
12. Mar 19 Buy Jubilant Corporation Company 07. Mar 19 07. Mar 19 650,000 ₹765.85 ₹497,802,478
11. Mar 19 Sell Vimal Kulshrestha Individual 27. Feb 19 07. Mar 19 -1,800 ₹791.20 ₹-1,406,857
05. Mar 19 Sell Rajesh Srivastava Individual 26. Feb 19 26. Feb 19 -5,000 ₹771.88 ₹-3,859,394
10. Dec 18 Sell Vimal Kulshrestha Individual 04. Dec 18 06. Dec 18 -3,000 ₹813.72 ₹-2,441,174
X
Management checks
We assess Jubilant Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Jubilant Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Jubilant Life Sciences Limited manufactures and supplies active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products, advance intermediates, fine ingredients, crop science ingredients, life science chemicals, and nutritional products. The company offers APIs in the cardiovascular system, central nervous system, and anti-infective therapeutic areas; and develops dosage forms, including oral solid, injectable, and ophthalmic dosage forms. It is also involved in the contract manufacturing of sterile injectables, ointments, creams and liquids, allergy therapy products, and radiopharmaceutical products; manufacture and market of radiopharmaceuticals for the diagnosis, treatment, and monitoring of various diseases; business of licensing generic dosage forms and providing regulatory services to generic pharmaceutical companies; and supply of generic dosage forms and bulk chemicals, such as ethyl acetate, acetic anhydride, etc., as well as vitamins to the European markets. In addition, the company offers drug discovery services to pharmaceutical and biotech companies; and services in synthetic organic chemistry, combinatorial chemistry, medicinal chemistry, process research and development, scale up services, and GMP manufacturing-clinical supply to drug discovery companies in the United States, Europe, and internationally. Further, it sells and distributes advance intermediates, vitamins, life science chemicals, and fine ingredients in North America; and trades in advance intermediates, specialty ingredients, and nutrition products for the pharmaceutical, animal feed, and agrochemical industries in China. Additionally, the company operates a network of 50 radiopharmacies across approximately 20 states in the United States. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. The company was incorporated in 1978 and is based in Noida, India.

Details
Name: Jubilant Life Sciences Limited
530019
Exchange: BSE
Founded: 1978
₹73,447,592,823
155,774,322
Website: http://www.jubl.com
Address: Jubilant Life Sciences Limited
1A, Sector 16A,
Noida,
Uttar Pradesh, 201301,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BSE 530019 Equity Shares Mumbai Stock Exchange IN INR 02. Jan 1992
NSEI JUBILANT Equity Shares National Stock Exchange of India IN INR 02. Jan 1992
Number of employees
Current staff
Staff numbers
7,700
Jubilant Life Sciences employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 12:47
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/05/22
Last earnings filing: 2019/05/17
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.